Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Tango Therapeutics Inc. — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $77.2 (market cap $158.70B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 42.3× Tango Therapeutics Inc.'s market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (9,865,871 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 59 Days and Tango Therapeutics Inc. for 0 Days on average.
| IEMG | TNGX | |
|---|---|---|
Market Cap | $158.70B | $3.75B |
Volume | 9,865,871 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $32.90 |
52-Week Low | $64.72 | $7.50 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
